Table of Contents

• What is Benserazide Hydrochloride?
• Combination with Levodopa
• Medical Conditions Treated
• Dosage and Administration
• Eligibility Criteria for Treatment
• Potential Side Effects and Monitoring

What is Benserazide Hydrochloride?

Benserazide Hydrochloride is a medication commonly used in the treatment of Parkinson’s disease. It belongs to a class of drugs known as decarboxylase inhibitors. While Benserazide itself doesn’t directly treat Parkinson’s symptoms, it plays a crucial role in enhancing the effectiveness of another important medication called Levodopa^[1].

Combination with Levodopa

Benserazide Hydrochloride is typically combined with Levodopa in a single tablet. This combination is known by various brand names, including Madopark. The specific formulation mentioned in the clinical trial data is “Madopark 100 mg/25 mg tablets,” which contains 100 mg of Levodopa and 25 mg of Benserazide Hydrochloride^[1].

The reason for this combination is that Benserazide helps prevent the breakdown of Levodopa before it reaches the brain. This allows more Levodopa to cross the blood-brain barrier, increasing its effectiveness in treating Parkinson’s symptoms^[1].

Medical Conditions Treated

The primary condition treated by the Benserazide-Levodopa combination is Parkinson’s disease. Parkinson’s is a progressive nervous system disorder that affects movement. Symptoms may include tremors, stiffness, and difficulty with balance and coordination^[1].

This medication is particularly useful for patients with:

• Early to moderate Parkinson’s disease: The clinical trial data suggests it’s used in patients with a clinical diagnosis of less than 4 years and a Hoehn and Yahr stage (a measure of Parkinson’s progression) of 2 or less^[1].
• Motor symptoms: The primary goal of treatment is to improve motor symptoms, which are measured using a scale called the MDS-UPDRS Part 3^[1].
• Non-motor symptoms: The medication may also help with non-motor symptoms of Parkinson’s disease^[1].

Dosage and Administration

According to the clinical trial data:

• The medication is taken orally in tablet form^[1].
• The maximum daily dose is 1800 mg^[1].
• The maximum total dose over the course of treatment is 1,314,000 mg^[1].
• The maximum treatment period is 24 months^[1].

It’s important to note that these are maximum doses, and your doctor will prescribe the appropriate dose for your specific condition. Always follow your doctor’s instructions regarding dosage and administration^[1].

Eligibility Criteria for Treatment

Based on the clinical trial information, the following criteria are considered for treatment eligibility:

Inclusion Criteria:

• Age between 35 and 80 years^[1]
• Clinical diagnosis of Parkinson’s disease for less than 4 years^[1]
• Hoehn and Yahr stage 2 or less in the OFF medication state (This scale measures the progression of Parkinson’s disease)^[1]
• Already on ongoing levodopa treatment^[1]
• Ability to self-administer the medication^[1]

Exclusion Criteria:

• Previous or concurrent depression requiring hospitalization^[1]
• Severe liver or kidney disease^[1]
• Concurrent moderate-to-severe depression^[1]
• Concurrent dementia^[1]
• Active oral mucosa inflammation^[1]
• Active Hepatitis B or C infection^[1]
• Atypical or other causes of parkinsonism^[1]
• Prior intra-cerebral surgical intervention^[1]

It’s crucial to discuss your full medical history with your doctor to determine if this medication is appropriate for you^[1].

Potential Side Effects and Monitoring

While the clinical trial data doesn’t provide specific information about side effects of Benserazide Hydrochloride, it does mention that the study will examine:

• The frequency of adverse events in patients taking the medication compared to those on placebo^[1]
• Changes in vital signs^[1]
• Changes in clinical laboratory values^[1]

Your doctor will monitor these aspects during your treatment. It’s important to report any unusual symptoms or side effects to your healthcare provider promptly^[1].